Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Merck Serono Files Bavencio in Japan for First-Line Use in RCC
January 31, 2019
- Takeda’s Tetravalent Dengue Vaccine Succeeds in PIII Study
January 31, 2019
- Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
January 31, 2019
- Kymriah Study Drugs to Be Manufactured in Kobe: Novartis
January 30, 2019
- Stem Cell Therapy SB623 Misses Key Target in US PIIb Study for Stroke: SanBio, Sumitomo Dainippon
January 30, 2019
- Protosera, Fujita Health Univ. Tie Up for Research to Develop Treatments for Autism Spectrum Disorder
January 30, 2019
- China Approves Latuda for Schizophrenia: Sumitomo Dainippon
January 30, 2019
- Takeda to Book 38 Billion Yen Gain from Sale of Osaka HQ, Other Assets
January 29, 2019
- Ex-MHLW Bureau Chief Takeda Tapped as Senior Adviser at BCG
January 29, 2019
- Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales
January 29, 2019
- Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show
January 28, 2019
- Tamiflu Generics, Too, in Tight Supply amid Spike in Flu Patients
January 28, 2019
- Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
January 25, 2019
- Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
- Shionogi, PeptiDream Join Forces for Novel Peptide Drug-Conjugate Discovery Research
January 24, 2019
- Mitsubishi Tanabe Shooting for 100 Billion Yen Sales in US/Europe, 50% Overseas Ratio
January 23, 2019
- Astellas to Transfer Dormicum to Maruishi
January 23, 2019
- Astellas, Kaketsuken Successor End Vaccine, Blood Product Pact
January 23, 2019
- SanBio’s Cell Therapy to Be Developed for Brain Bleeding Too
January 22, 2019
- Shionogi Upping Xofluza Production to Get Back to Normal before Flu Season Ends
January 22, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…